| Overcoming the blood–brain tumor barrier for effective glioblastoma treatment O van Tellingen, B Yetkin-Arik, MC de Gooijer, P Wesseling, T Wurdinger, ... Drug Resistance Updates 19, 1-12, 2015 | 905 | 2015 |
| ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy F Lin, MC de Gooijer, EM Roig, LCM Buil, SM Christner, JH Beumer, ... Clinical Cancer Research 20 (10), 2703-2713, 2014 | 127 | 2014 |
| An experimenter’s guide to glioblastoma invasion pathways MC de Gooijer, MG Navarro, R Bernards, T Wurdinger, O van Tellingen Trends in Molecular Medicine 24 (9), 763-780, 2018 | 114 | 2018 |
| Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2 MC de Gooijer, NA de Vries, T Buckle, LCM Buil, JH Beijnen, W Boogerd, ... Neoplasia 20 (7), 710-720, 2018 | 107 | 2018 |
| P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib MC de Gooijer, P Zhang, N Thota, I Mayayo-Peralta, LCM Buil, JH Beijnen, ... Investigational New Drugs 33 (5), 1012-1019, 2015 | 86 | 2015 |
| Glycosylated extracellular vesicles released by glioblastoma cells are decorated by CCL18 allowing for cellular uptake via chemokine receptor CCR8 J Berenguer, T Lagerweij, XW Zhao, S Dusoswa, P van der Stoop, ... Journal of Extracellular Vesicles 7 (1), 1446660, 2018 | 81 | 2018 |
| Identification of a Druggable Pathway Controlling Glioblastoma Invasiveness N Pencheva, MC de Gooijer, DJ Vis, LFA Wessels, T Würdinger, ... Cell Reports 20 (1), 48-60, 2017 | 77 | 2017 |
| ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2‐Inhibitors P Zhang, MC de Gooijer, L Buil, JH Beijnen, G Li, O van Tellingen International Journal of Cancer 137 (8), 2007-2018, 2015 | 76 | 2015 |
| PI3K–mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models F Lin, MC de Gooijer, D Hanekamp, G Chandrasekaran, LCM Buil, ... Clinical Cancer Research 23 (5), 1286-1298, 2017 | 72 | 2017 |
| Tryptophan depletion results in tryptophan-to-phenylalanine substitutants A Pataskar, J Champagne, R Nagel, J Kenski, M Laos, J Michaux, HS Pak, ... Nature 603 (7902), 721-727, 2022 | 65 | 2022 |
| The impact of P‐glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors MC de Gooijer, P Zhang, R Weijer, L Buil, JH Beijnen, O van Tellingen International journal of cancer 142 (2), 381-391, 2018 | 61 | 2018 |
| The G2 checkpoint: a node‐based molecular switch MC de Gooijer, A den Top, I Bockaj, JH Beijnen, T Würdinger, O Tellingen FEBS Open Bio, 2017 | 61 | 2017 |
| Buparlisib is a brain penetrable pan-PI3K inhibitor MC de Gooijer, P Zhang, LCM Buil, CH Çitirikkaya, N Thota, JH Beijnen, ... Scientific Reports 8 (1), 10784, 2018 | 55 | 2018 |
| Combined therapy of AXL and HDAC inhibition reverses mesenchymal transition in diffuse intrinsic pontine glioma MH Meel, MC de Gooijer, DS Metselaar, ACP Sewing, K Zwaan, ... Clinical Cancer Research 26 (13), 3319-3332, 2020 | 53 | 2020 |
| ATP-binding cassette transporters restrict drug delivery and efficacy against brain tumors even when blood-brain barrier integrity is lost MC de Gooijer, EM Kemper, LCM Buil, CH Çitirikkaya, T Buckle, ... Cell Reports Medicine 2 (1), 100184, 2021 | 47 | 2021 |
| Directed Molecular Evolution Reveals Gaussia Luciferase Variants with Enhanced Light Output Stability MH Degeling, MSS Bovenberg, GK Lewandrowski, MC de Gooijer, ... Analytical chemistry 85 (5), 3006-3012, 2013 | 47 | 2013 |
| MELK Inhibition in Diffuse Intrinsic Pontine Glioma MH Meel, MC de Gooijer, MG Navarro, P Waranecki, M Breur, LCM Buil, ... Clinical Cancer Research 24 (22), 5645-5657, 2018 | 36 | 2018 |
| Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype J Teng, S Hejazi, L Hiddingh, L Carvalho, MC de Gooijer, H Wakimoto, ... Neuro-oncology 20 (5), 642-654, 2017 | 36 | 2017 |
| MEK/MELK inhibition and blood-brain barrier-deficiencies in atypical teratoid/rhabdoid tumors MH Meel, M Guillén Navarro, MC de Gooijer, DS Metselaar, P Waranecki, ... Neuro-Oncology, 2019 | 25 | 2019 |
| Treating Tumors Using TTFields Combined with ABT-751 G Borst, O Van Tellingen, M Giladi, MC De Gooijer, PLG Slangen US Patent App. 16/593,081, 2020 | 24 | 2020 |
Olaf van TellingenNetherlands Cancer InstituteGeverifieerd e-mailadres voor nki.nl
